Key Drivers
- High cash runway
- No revenue
- Heavy cash burn
AIAI Summary
COGT has shifted from long‑dated optionality to a near‑term, binary 2026 commercialization bet—bezuclastinib NDA approvals and a successful H2‑2026 launch now drive value, so position size should hinge on positive regulatory readouts, early uptake/payer wins, and controlled cash burn to avoid dilution.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High cash runway
- •No revenue
- •Heavy cash burn
COGT has strong liquidity and low leverage but no revenue and large R&D/investment-driven cash burn producing negative operating and free cash flow, forcing reliance on external financing to sustain operations.
Price Behavior
Key Price Behavior Insights:
- •Below last month SMA
- •Overbought then pullback
- •Elevated short-term volatility
COGT closed below its last month SMA (~$36.77) on 2026-03-20 with RSI ~72 and a sharp pullback from late‑February highs, signaling short‑term weakness toward $33.38 support amid elevated volatility.
~16% drop from late‑February peaks to the 2026-03-20 low indicating elevated short-term volatility
Sentiment & News
Key News Insights:
- •FDA NDA acceptance
- •Robust SUMMIT data
- •Large share swings
Cogent's bezuclastinib showed strong SUMMIT efficacy and secured FDA NDA acceptance for non‑advanced systemic mastocytosis (PDUFA ~2026‑12‑30), triggering outsized share moves amid a ~$900M cash runway but ongoing R&D losses and some insider selling.
Positive clinical and regulatory momentum materially raises approval and commercialization prospects, likely driving near‑term investor interest and volatility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings